31 results
Thumbnail

D2.314 - Late Presentation of Cutaneous Chronic Graft Versus Host Disease – A Case Report

Thumbnail

D2.309 - Descriptive Study of Chronic Urticaria Under Treatment with Omalizumab: Our Experience

Thumbnail

D2.310 - Dysregulation of barrier function and distribution of nerve cells in a mouse model of atopic dermatitis

Thumbnail

D2.311 - Real World Web Survey on the Burden of Urticaria

Thumbnail

D2.312 - Impact of metabolic disorders on immune dysregulation in psoriasis and atopic dermatitis

Thumbnail

D2.313 - Importance of non-itchy erythema marginatum as a prodromal symptom of hereditary angioedema attacks

Thumbnail

D2.315 - Clinical features and Progress of Diagnosis and Therapy of Hereditary Angioedema in China: A Systemic Review of Published Cases

Thumbnail

D2.316 - The role of Tumor necrosis factor ligand superfamily member 15 in Atopic dermatitis

Thumbnail

D2.317 - The role of sirtuin 2 (SIRT2) in atopic dermatitis

Thumbnail

D2.318 - Triggers and prodromal indicators of angioedema attacks in hereditary angioedema patients

Thumbnail

D2.319 - Advancing Diagnosis and Management of Hereditary Angioedema in Brazil: Insights from the first 704 patients of a Multicenter Registry

Thumbnail

D2.322 - Quality of life of families with children suffering from chronic urticaria

Thumbnail

D2.323 - Higher neonatal urinary phthalate are associated with the development of infantile atopic dermatitis

Thumbnail

D2.324 - Psychological Burden Associated with Injectable HAE On-Demand Treatments: A Patient and Caregiver Interview Study

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes